Headlines about Fluidigm Corporation (NASDAQ:FLDM) have been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fluidigm Corporation earned a coverage optimism score of 0.05 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 44.6516280720816 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the media headlines that may have impacted Accern’s analysis:

Fluidigm Corporation (NASDAQ:FLDM) last announced its earnings results on Thursday, August 3rd. The medical research company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.02. The business had revenue of $23.90 million during the quarter, compared to the consensus estimate of $23.50 million. Fluidigm Corporation had a negative return on equity of 121.04% and a negative net margin of 74.05%. The business’s quarterly revenue was down 15.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.63) EPS.

ILLEGAL ACTIVITY NOTICE: “Fluidigm Corporation (FLDM) Receiving Somewhat Favorable News Coverage, Analysis Finds” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/10/13/fluidigm-corporation-fldm-receiving-somewhat-favorable-news-coverage-analysis-finds.html.

In other Fluidigm Corporation news, CEO Stephen Christopher Linthwaite bought 45,000 shares of Fluidigm Corporation stock in a transaction dated Tuesday, August 8th. The stock was acquired at an average cost of $2.66 per share, with a total value of $119,700.00. Following the purchase, the chief executive officer now directly owns 106,977 shares in the company, valued at approximately $284,558.82. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, insider Steven Mcphail bought 20,000 shares of Fluidigm Corporation stock in a transaction dated Tuesday, August 8th. The shares were acquired at an average cost of $3.00 per share, with a total value of $60,000.00. Following the completion of the purchase, the insider now owns 27,842 shares in the company, valued at $83,526. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 4,311,881 shares of company stock valued at $14,478,585. Corporate insiders own 4.70% of the company’s stock.

About Fluidigm Corporation

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Insider Buying and Selling by Quarter for Fluidigm Corporation (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.